Calliditas Therapeutics' nomination committee for the AGM 2021
Calliditas Therapeutics AB has announced the composition of its nomination committee for the 2021 Annual General Meeting (AGM). The committee includes Patrick Sobocki, Spike Loy, Karl Tobieson, and Elmar Schnee as chairman. Their responsibilities will involve preparing proposals for the elections of board members, auditors, and fee determinations ahead of the AGM scheduled for May 27, 2021. Shareholders can submit proposals to the committee until April 5, 2021. Calliditas is focused on developing treatments for orphan diseases, including its lead product candidate, Nefecon.
- Calliditas is preparing for its 2021 AGM, which enhances shareholder engagement.
- The nomination committee consists of key industry figures, potentially improving governance.
- None.
STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021.
The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017, consists of:
· Patrick Sobocki, appointed by Stiftelsen Industrifonden
· Spike Loy, appointed by BVF
· Karl Tobieson, appointed by Linc AB
· Elmar Schnee (chairman of the board of directors)
The nomination committee shall, before the annual general meeting 2021, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, election of auditors, the determination of fees and matters pertaining thereto.
For more information please visit:
https://www.calliditas.se/en/nomination-committee-2314/
Shareholders who wish to submit proposals to the nomination committee for the annual general meeting on May 27, 2021 can do so by e-mail to finance@calliditas.com. Proposals should be submitted to the nomination committee before April 5, 2021.
For further information, please contact:
Fredrik Johansson, CFO at Calliditas
Email: fredrik.johansson@calliditas.com
Telephone: +46 703 52 91 90
The information was submitted for publication, through the agency of the contact person set out above, at 4.00 p.m on November 27, 2020.
About Calliditas Therapeutics
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-nomination-committee-for-the-agm-2021-301181201.html
SOURCE Calliditas Therapeutics
FAQ
Who is on the nomination committee for Calliditas Therapeutics 2021 AGM?
What is the deadline for submitting proposals to Calliditas' nomination committee?
When is the Calliditas Therapeutics Annual General Meeting scheduled?
What is the focus of Calliditas Therapeutics?
